Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,032.83
-14.08 (-1.34%)
Streaming Delayed Price
Updated: 10:06 AM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
40
41
Next >
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
February 28, 2022
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein.
Via
Investor's Business Daily
Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
February 28, 2022
Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended...
Via
Benzinga
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
February 25, 2022
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.
Via
InvestorPlace
7 Low Volatility Stocks to Buy Right Now for Steady Returns
February 24, 2022
A great way to find low volatility stocks is to look for a beta that's less than 1.0. Here are seven to buy as market turbulence increases.
Via
InvestorPlace
KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?
February 23, 2022
Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session.
Via
InvestorPlace
S&P 500 Slips Further into Correction Territory as Stocks Give Up Gains
February 23, 2022
Stocks have pulled back from this morning's gains, amid the ongoing Russia-Ukraine border crisis, with all three benchmarks looking to extend their losing streaks.
Via
Talk Markets
Kodiak Stock Pummeled After Attempt To Improve On Regeneron's Blockbuster Backfired
February 23, 2022
Kodiak hoped a less frequent dosing plan would benefit patients with an eye disease.
Via
Investor's Business Daily
Why Kodiak Sciences Shares Are Plunging Today
February 23, 2022
Kodiak Sciences Inc (NASDAQ: KOD) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-...
Via
Benzinga
Is Moderna the Next Gilead or the Next Regeneron?
February 22, 2022
MRNA stock is seen purely as a Covid-19 play. Until Moderna can prove it's not a one-hit wonder, shares are likely to remain depressed.
Via
InvestorPlace
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
February 18, 2022
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab...
Via
Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
February 17, 2022
Can the formerly red-hot biotech segment return to its previous glory?
Via
Investor's Business Daily
Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade
February 14, 2022
Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Large Cap Biopharma- Well Positioned For Choppy Markets
February 14, 2022
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets.
Via
Talk Markets
5 Value Stocks To Watch In The Healthcare Sector
February 14, 2022
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...
Via
Benzinga
Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19
February 14, 2022
The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized...
Via
Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
February 11, 2022
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.
Via
Investor's Business Daily
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
February 10, 2022
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)
Via
Benzinga
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
February 10, 2022
The
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
February 08, 2022
Keybanc raised Take-Two Interactive Software, Inc. (NASDAQ: TTWO) price target from $185 to $190. Take-Two Interactive shares fell 2.8% to $170.21 in pre-market trading.
Via
Benzinga
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
February 07, 2022
The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79.
Via
Investor's Business Daily
Cathie Wood's Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings
February 05, 2022
Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed.
Via
Benzinga
Stock Market Rally Volatile; Google, Facebook, Amazon, Snap Are Earnings Movers: Weekly Review
February 04, 2022
The major indexes slashed weekly gains after Monday's follow-through day.
Via
Investor's Business Daily
Regeneron Scores Quarterly Beat On Covid Cocktail — But Future Sales Are Shaky
February 04, 2022
Regeneron posted 104% sales growth, including $2.3 billion from REGEN-COV.
Via
Investor's Business Daily
Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales
February 04, 2022
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned
Via
Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Recap: Regeneron Pharmaceuticals Q4 Earnings
February 04, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 4, 2022
February 04, 2022
Companies Reporting Before The Bell • Brookfield Business (NYSE:BBU) is estimated to report earnings for its fourth quarter.
Via
Benzinga
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.